Recently, Jiudian Pharmaceutical's Crizotinol Ointment officially received registration approval from the National Medical Products Administration, which is considered equivalent to passing the generic drug consistency evaluation. This product is a Class B drug covered by the National Medical Insurance Program and is suitable for the topical treatment of mild to moderate atopic dermatitis in children aged 3 months and older and adults. This approval marks a new breakthrough for Jiudian Pharmaceutical in the field of topical medications, further expanding the therapeutic indications of its topical product portfolio from the anti-inflammatory and analgesic field to the field of skin immune inflammation regulation.

Atopic dermatitis is a chronic, relapsing, inflammatory skin disease, and its prevalence among children in my country is showing an increasing trend year by year. For a long time, topical treatment for mild to moderate atopic dermatitis has mainly relied on corticosteroids and calcineurin inhibitors. However, long-term use of corticosteroids carries risks, and some medications are restricted for use in young children, indicating a clear unmet clinical need.
Criborone is a novel small-molecule, non-hormonal, non-steroidal anti-inflammatory phosphodiesterase 4 (PDE-4) inhibitor. It effectively relieves symptoms such as skin inflammation, erythema, and itching by inhibiting intracellular PDE-4 activity and reducing the production of pro-inflammatory cytokines. Criborone is the first non-hormonal topical PDE-4 inhibitor approved in China and is currently the only approved topical PDE-4 inhibitor in China for use in patients aged 3 months and older with mild to moderate atopic dermatitis.
This product was once included in the second batch of urgently needed overseas new drugs in China. It boasts good efficacy, precise targeting, and excellent penetration, bringing greater convenience to patients with atopic dermatitis. Since the original drug was approved for marketing in China in July 2020, the market size of criborone ointment has grown rapidly. In 2021, its growth rate in urban and county-level public hospitals exceeded 1300%. By 2024, the sales of this product in the three major domestic terminals had reached nearly 200 million yuan, with a three-year compound annual growth rate of 95.03%, demonstrating extremely high market recognition and broad development prospects.
Jiudian Pharmaceutical has cultivated a deep expertise in the field of topical transdermal drug delivery, particularly in local analgesia, where it has established a strong reputation in the industry. The official approval of clarithromycin ointment further enriches Jiudian Pharmaceutical's portfolio of topical products. In the future, Jiudian Pharmaceutical will continue to focus on clinical needs, accelerate its research and development, and produce more new and effective drugs to benefit the general public.

https://bydrug.pharmcube.com/news/detail/30598266f1191106e103ef82f39a1e4b